复发性卵巢癌二次肿瘤细胞减灭术中微创手术与开腹手术的围手术期及肿瘤学结局比较
微创手术组完全肉眼切除率95%、开腹组93%(P=1.0),中位估计出血量50cm³ vs 150cm³(P=0.001),中位住院时间1天 vs 5天(P<0.001),并发症8% vs 22%(P=0.06)。两组2年无进展生存率和总生存率无显著差异。
要点
- 在适当选择的病例中,复发性卵巢癌二次肿瘤细胞减灭术采用微创手术是可行的。
- 微创手术组完全肉眼切除率95%,开腹组93%(P=1.0),两组无显著差异。
- 微创手术组中位估计出血量50cm³、住院1天,均优于开腹组的150cm³和5天。
核心结论
- 在适当选择的病例中,复发性卵巢癌二次肿瘤细胞减灭术采用微创手术是可行的,围手术期结局良好,肿瘤学结局与开腹手术相似。
研究设计与样本
- 微创手术或开腹手术的选择基于外科医生偏好;为减少选择偏倚,回顾所有开腹病例的术前影像以识别潜在微创手术候选者用于比较。
- 共识别170例(开腹131例、腹腔镜8例、机器人辅助31例);可行性分析纳入开腹68例和微创39例,采用意向性治疗分析进行统计检验。
主要发现
- 微创手术组6例(15%)中转开腹。
- 两组中位年龄、体质指数、手术时间无显著差异。
- 完全肉眼切除:微创手术组37/39(95%),开腹手术组63/68(93%)(P=1.0)。
- 中位估计出血量:微创手术组50cm³(范围5-500),开腹手术组150cm³(范围0-1500)(P=0.001)。
- 中位住院时间:微创手术组1天(范围0-23),开腹手术组5天(范围1-21)(P<0.001);并发症:微创手术组3/39(8%),开腹手术组15/68(22%)(P=0.06)。
临床怎么用
- 原文结论认为,在适当选择的病例中,复发性卵巢癌二次肿瘤细胞减灭术采用微创手术是可行的,且围手术期结局良好、肿瘤学结局与开腹手术相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the perioperative outcomes of minimal access surgery (MAS) in secondary surgical cytoreduction (SSCR) for recurrent epithelial ovarian cancer (ROC); to compare oncologic outcomes with laparotomy (LAP). METHODS: Using an institutional database, we identified all patients with ROC undergoing SSCR from 1/5/09-6/14/14. Selection for MAS or LAP was based on surgeon preference. To minimize selection bias, preoperative imaging was reviewed for all LAP cases. In this manner, we identified potential MAS candidates, who were used in the comparison. Intent-to-treat analyses were undertaken using statistical testing. RESULTS: 170 cases were identified (131 LAP, 8 LSC, 31 RBT). 68/131 (52%) LAP cases were deemed potential candidates for MAS. Feasibility analyses included 68 LAP and 39 MAS cases. Six (15%) MAS cases were converted to LAP. Median age, BMI, operative time did not differ significantly between the groups. Complete gross resection was achieved in 37/39 (95%) MAS, 63/68 (93%) LAP (P=1.0). Median estimated blood loss was 50cm3 (range, 5-500) MAS, 150cm3 (range, 0-1500) LAP (P=0.001). Median length of stay was 1day (range, 0-23) MAS, 5days (range, 1-21) LAP (P<0.001). Complications occurred in 3/39 (8%) MAS, 15/68 (22%) LAP (P=0.06). The 2-year progression-free survival was 56.1% (SE 9%) MAS, 63.5% (SE 6%) LAP (P=1.0). The 2-year overall survival was 92.2% (SE 5.4%) MAS, 81.4% (SE 5.5%) LAP (P=0.7). CONCLUSIONS: MAS for SSCR is feasible in properly selected cases. MAS is associated with favorable perioperative outcomes and similar oncologic outcomes, compared to LAP.
引用
- Eriksson AGZ, Graul A, Yu MC, et al. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecol Oncol. 2017. PMID: 28527673. doi:10.1016/j.ygyno.2017.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。